Dianthus Therapeutics (DNTH) Gains from Investment Securities: 2017-2025
Historic Gains from Investment Securities for Dianthus Therapeutics (DNTH) over the last 3 years, with Sep 2025 value amounting to $5.0 million.
- Dianthus Therapeutics' Gains from Investment Securities rose 3894.40% to $5.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $6.0 million, marking a year-over-year increase of 934.31%. This contributed to the annual value of $4.5 million for FY2024, which is 157.20% up from last year.
- Latest data reveals that Dianthus Therapeutics reported Gains from Investment Securities of $5.0 million as of Q3 2025, which was up 1,069.32% from $427,000 recorded in Q2 2025.
- In the past 5 years, Dianthus Therapeutics' Gains from Investment Securities registered a high of $5.9 million during Q1 2025, and its lowest value of -$3.3 million during Q2 2023.
- Over the past 3 years, Dianthus Therapeutics' median Gains from Investment Securities value was $446,000 (recorded in 2024), while the average stood at $1.2 million.
- Its Gains from Investment Securities has fluctuated over the past 5 years, first plummeted by 96.29% in 2024, then surged by 3,894.40% in 2025.
- Dianthus Therapeutics' Gains from Investment Securities (Quarterly) stood at -$46,000 in 2023, then skyrocketed by 1,154.35% to $485,000 in 2024, then soared by 3,894.40% to $5.0 million in 2025.
- Its Gains from Investment Securities was $5.0 million in Q3 2025, compared to $427,000 in Q2 2025 and $5.9 million in Q1 2025.